12,296 Shares in iShares Nasdaq Biotechnology ETF (IBB) Acquired by Canal Capital Management LLC

Canal Capital Management LLC purchased a new stake in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 12,296 shares of the financial services provider’s stock, valued at approximately $1,186,000.

Several other institutional investors have also recently added to or reduced their stakes in IBB. Morgan Stanley lifted its holdings in iShares Nasdaq Biotechnology ETF by 3.7% in the 3rd quarter. Morgan Stanley now owns 4,026,110 shares of the financial services provider’s stock worth $490,944,000 after purchasing an additional 143,209 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in iShares Nasdaq Biotechnology ETF by 36.2% in the 3rd quarter. Alliancebernstein L.P. now owns 737,179 shares of the financial services provider’s stock worth $89,892,000 after purchasing an additional 195,746 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in iShares Nasdaq Biotechnology ETF by 4.9% in the 3rd quarter. PNC Financial Services Group Inc. now owns 670,311 shares of the financial services provider’s stock worth $81,736,000 after purchasing an additional 31,175 shares in the last quarter. Lockheed Martin Investment Management Co. lifted its holdings in iShares Nasdaq Biotechnology ETF by 173.9% in the 4th quarter. Lockheed Martin Investment Management Co. now owns 417,400 shares of the financial services provider’s stock worth $40,250,000 after purchasing an additional 265,000 shares in the last quarter. Finally, Bank of Montreal Can lifted its holdings in iShares Nasdaq Biotechnology ETF by 21.2% in the 4th quarter. Bank of Montreal Can now owns 356,482 shares of the financial services provider’s stock worth $34,376,000 after purchasing an additional 62,272 shares in the last quarter. Institutional investors and hedge funds own 66.51% of the company’s stock.

NASDAQ IBB opened at $107.80 on Monday. iShares Nasdaq Biotechnology ETF has a 12 month low of $89.01 and a 12 month high of $122.97.

TRADEMARK VIOLATION NOTICE: “12,296 Shares in iShares Nasdaq Biotechnology ETF (IBB) Acquired by Canal Capital Management LLC” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2019/02/11/12296-shares-in-ishares-nasdaq-biotechnology-etf-ibb-acquired-by-canal-capital-management-llc.html.

About iShares Nasdaq Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Further Reading: What are convertible shares? 

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply